| Market Cap | 1.53B | P/E | - | EPS this Y | -690.00% | Ern Qtrly Grth | - |
| Income | -165.87M | Forward P/E | 8.03 | EPS next Y | 53.80% | 50D Avg Chg | -3.00% |
| Sales | 298.76M | PEG | 0.00 | EPS past 5Y | - | 200D Avg Chg | -27.00% |
| Dividend | N/A | Price/Book | 4.34 | EPS next 5Y | -230.20% | 52W High Chg | -46.00% |
| Recommedations | 2.90 | Quick Ratio | 4.48 | Shares Outstanding | 68.08M | 52W Low Chg | 44.00% |
| Insider Own | 14.35% | ROA | -28.28% | Shares Float | 49.19M | Beta | -0.62 |
| Inst Own | 86.58% | ROE | -51.22% | Shares Shorted/Prior | 1.26M/1.97M | Price | 22.80 |
| Gross Margin | 8.52% | Profit Margin | -55.52% | Avg. Volume | 1,136,504 | Target Price | 4.25 |
| Oper. Margin | 7,457.09% | Earnings Date | Aug 8 | Volume | 815,083 | Change | -2.48% |
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
| Goldman Sachs | Neutral | Jul 12, 24 |
| HC Wainwright & Co. | Buy | Jul 10, 24 |
| HC Wainwright & Co. | Buy | Jun 24, 24 |
| Mizuho | Neutral | May 14, 24 |
| HC Wainwright & Co. | Buy | May 10, 24 |
| Baird | Neutral | Apr 11, 24 |
| HC Wainwright & Co. | Buy | Apr 11, 24 |
| HC Wainwright & Co. | Buy | Apr 8, 24 |
| HC Wainwright & Co. | Buy | Mar 12, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Klee Justin B. | Co-Chief Executive O.. Co-Chief Executive Officer | Jan 09 | Sell | 16.3281 | 5,841 | 95,372 | 2,836,776 | 01/11/24 |
| FRATES JAMES M | Chief Financial Offi.. Chief Financial Officer | Jan 09 | Sell | 16.3281 | 2,716 | 44,347 | 112,035 | 01/11/24 |
| Cohen Joshua B | Co-Chief Executive O.. Co-Chief Executive Officer | Jan 09 | Sell | 16.3281 | 5,841 | 95,372 | 2,900,470 | 01/11/24 |
| Yeramian Patrick D | Chief Medical Office.. Chief Medical Officer | Jan 09 | Sell | 16.3281 | 2,812 | 45,915 | 205,605 | 01/11/24 |
| Cohen Joshua B | Co-Chief Executive O.. Co-Chief Executive Officer | Nov 16 | Option | 1.57 | 63,694 | 100,000 | 2,906,311 | 11/20/23 |
| FRATES JAMES M | Chief Financial Offi.. Chief Financial Officer | May 16 | Sell | 27.26 | 32,500 | 885,950 | 55,676 | 05/18/23 |
| FRATES JAMES M | Chief Financial Offi.. Chief Financial Officer | May 16 | Option | 6.88 | 32,500 | 223,600 | 88,176 | 05/18/23 |
| Yeramian Patrick D | Chief Medical Office.. Chief Medical Officer | Apr 17 | Sell | 30.74 | 49,579 | 1,524,058 | 208,417 | 04/19/23 |
| Yeramian Patrick D | Chief Medical Office.. Chief Medical Officer | Apr 17 | Option | 3.63 | 49,579 | 179,972 | 257,996 | 04/19/23 |
| FRATES JAMES M | Chief Financial Offi.. Chief Financial Officer | Mar 16 | Sell | 32.16 | 32,500 | 1,045,200 | 34,009 | 03/24/23 |
| FRATES JAMES M | Chief Financial Offi.. Chief Financial Officer | Mar 16 | Option | 6.88 | 32,500 | 223,600 | 66,509 | 03/24/23 |
| Yeramian Patrick D | Chief Medical Office.. Chief Medical Officer | Mar 16 | Sell | 32.14 | 54,627 | 1,755,712 | 199,250 | 03/24/23 |
| Yeramian Patrick D | Chief Medical Office.. Chief Medical Officer | Mar 16 | Option | 2.53 | 49,578 | 125,432 | 253,877 | 03/24/23 |
| Klee Justin B. | Co-Chief Executive O.. Co-Chief Executive Officer | Mar 16 | Sell | 32.16 | 100,000 | 3,216,000 | 2,792,617 | 03/20/23 |
| MILNE GEORGE M JR | Director Director | Mar 16 | Sell | 32.15 | 35,000 | 1,125,250 | 862,021 | 03/20/23 |
| Firestone Karen | Director Director | Mar 16 | Buy | 31.99 | 1,000 | 31,990 | 1,000 | 03/20/23 |
| Cohen Joshua B | Co-Chief Executive O.. Co-Chief Executive Officer | Mar 16 | Sell | 32.14 | 100,000 | 3,214,000 | 2,792,617 | 03/20/23 |
| Mazzariello Gina | Chief Legal Officer Chief Legal Officer | Feb 24 | Sell | 34.4874 | 3,586 | 123,672 | 37,414 | 02/28/23 |
| Yeramian Patrick D | Chief Medical Office.. Chief Medical Officer | Jan 06 | Sell | 36.43 | 2,034 | 74,099 | 204,299 | 01/10/23 |
| Cohen Joshua B | Co-Chief Executive O.. Co-Chief Executive Officer | Jan 06 | Sell | 36.43 | 5,968 | 217,414 | 2,892,617 | 01/10/23 |
| FRATES JAMES M | Chief Financial Offi.. Chief Financial Officer | Jan 06 | Sell | 36.43 | 2,658 | 96,831 | 34,009 | 01/10/23 |
| Olinger Margaret | Chief Commercial Off.. Chief Commercial Officer | Jan 06 | Sell | 36.43 | 2,403 | 87,541 | 214,355 | 01/10/23 |
| Klee Justin B. | Co-Chief Executive O.. Co-Chief Executive Officer | Jan 06 | Sell | 36.43 | 5,968 | 217,414 | 2,892,617 | 01/10/23 |
| FRATES JAMES M | Chief Financial Offi.. Chief Financial Officer | Dec 30 | Option | 6.88 | 5,000 | 34,400 | 36,667 | 01/04/23 |
| VIKING GLOBAL INVESTORS LP | 10% Owner 10% Owner | Sep 08 | Sell | 29.95 | 1,400,000 | 41,930,000 | 1,850,940 | 09/09/22 |
| ALS Invest 1 B.V. | 10% Owner 10% Owner | Jul 06 | Sell | 20.97 | 60,609 | 1,270,971 | 5,895,280 | 07/08/22 |
| Morningside Venture Investment... | 10% Owner 10% Owner | Jan 06 | Buy | 19 | 263,158 | 5,000,002 | 10,678,808 | 03/17/22 |
| VIKING GLOBAL INVESTORS LP | 10% Owner 10% Owner | Jan 11 | Buy | 19 | 2,300,000 | 43,700,000 | 2,300,000 | 01/13/22 |
| FONTEYNE PAUL R. | Director Director | Jan 06 | Buy | 19.00 | 3,947 | 74,993 | 3,947 | 01/10/22 |
| Cheng Isaac | Director Director | Jan 06 | Buy | 19 | 6,578 | 124,982 | 6,578 | 01/10/22 |
| MILNE GEORGE M JR | Director Director | Jan 06 | Buy | 19.00 | 26,315 | 499,985 | 221,396 | 01/10/22 |
| Olinger Margaret | Chief Commercial Off.. Chief Commercial Officer | Jan 06 | Buy | 19 | 6,842 | 129,998 | 216,758 | 01/10/22 |